ORCID Profile
0000-0003-1150-5840
Current Organisations
Toronto General Research Institute
,
University of Toronto
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 14-07-2022
DOI: 10.1038/S41588-022-01113-Z
Abstract: The chr12q24.13 locus encoding OAS1–OAS3 antiviral proteins has been associated with coronavirus disease 2019 (COVID-19) susceptibility. Here, we report genetic, functional and clinical insights into this locus in relation to COVID-19 severity. In our analysis of patients of European ( n = 2,249) and African ( n = 835) ancestries with hospitalized versus nonhospitalized COVID-19, the risk of hospitalized disease was associated with a common OAS1 haplotype, which was also associated with reduced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance in a clinical trial with pegIFN-λ1. Bioinformatic analyses and in vitro studies reveal the functional contribution of two associated OAS1 exonic variants comprising the risk haplotype. Derived human-specific alleles rs10774671-A and rs1131454 -A decrease OAS1 protein abundance through allele-specific regulation of splicing and nonsense-mediated decay (NMD). We conclude that decreased OAS1 expression due to a common haplotype contributes to COVID-19 severity. Our results provide insight into molecular mechanisms through which early treatment with interferons could accelerate SARS-CoV-2 clearance and mitigate against severe COVID-19.
Publisher: Elsevier BV
Date: 07-2019
Publisher: Proceedings of the National Academy of Sciences
Date: 05-06-2023
Abstract: A hepatitis C virus (HCV) vaccine is urgently needed. Vaccine development has been hindered by HCV’s genetic ersity, particularly within the immunodominant hypervariable region 1 (HVR1). Here, we developed a strategy to elicit broadly neutralizing antibodies to HVR1, which had previously been considered infeasible. We first applied a unique information theory–based measure of genetic distance to evaluate phenotypic relatedness between HVR1 variants. These distances were used to model the structure of HVR1’s sequence space, which was found to have five major clusters. Variants from each cluster were used to immunize mice in idually, and as a pentavalent mixture. Sera obtained following immunization neutralized every variant in a erse HCVpp panel (n = 10), including those resistant to monovalent immunization, and at higher mean titers (1/ID 50 = 435) than a glycoprotein E2 (1/ID 50 = 205) vaccine. This synergistic immune response offers a unique approach to overcoming antigenic variability and may be applicable to other highly mutable viruses.
Location: United Kingdom of Great Britain and Northern Ireland
Location: United States of America
No related grants have been discovered for Adam Gehring.